Roche: encouraging results in breast cancer
(CercleFinance.com) - Roche was up on Tuesday's trading on the Zurich stock exchange following the publication of positive results from a study involving a new breast cancer drug.
The Swiss pharmaceutical group reports that its Itovebi tablet achieved a statistically significant and clinically relevant improvement in survival for patients with a form of advanced breast cancer known as HR positive.
While the Basel-based laboratory states that overall survival data are not yet 'mature', it notes that preliminary analyses show a 57% reduction in the risk of disease worsening or death compared to standard treatments (palbociclib and fulvestrant).
At this stage of the trial, overall survival reached 15 months, compared with 7.3 months in the control arm.
The study involved patients with locally advanced or metastatic PIK3CA-mutated, HR-positive but HER2-negative breast cancer resistant to endocrine therapy.
According to Roche, this is a form of the disease where the prognosis is generally poor, and where there is an urgent need for new treatment.
The stock is currently gaining around 1.1%, outperforming the SMI (+0.1%) as well as the STOXX 600 European health sub-index (0.7%).
Copyright (c) 2025 CercleFinance.com. All rights reserved.
The Swiss pharmaceutical group reports that its Itovebi tablet achieved a statistically significant and clinically relevant improvement in survival for patients with a form of advanced breast cancer known as HR positive.
While the Basel-based laboratory states that overall survival data are not yet 'mature', it notes that preliminary analyses show a 57% reduction in the risk of disease worsening or death compared to standard treatments (palbociclib and fulvestrant).
At this stage of the trial, overall survival reached 15 months, compared with 7.3 months in the control arm.
The study involved patients with locally advanced or metastatic PIK3CA-mutated, HR-positive but HER2-negative breast cancer resistant to endocrine therapy.
According to Roche, this is a form of the disease where the prognosis is generally poor, and where there is an urgent need for new treatment.
The stock is currently gaining around 1.1%, outperforming the SMI (+0.1%) as well as the STOXX 600 European health sub-index (0.7%).
Copyright (c) 2025 CercleFinance.com. All rights reserved.